Continuum News

Lyft and Continuum Announce Partnership for Clinical Trial Transportation Solutions


CHICAGO, Ill (January 24, 2017) – Today, Lyft and Continuum Clinical announced a partnership that will help to provide transportation solutions for patients who are enrolled in pharmaceutical clinical trials.

This partnership represents the first of its kind among pharmaceutical vendors who work on behalf of pharmaceutical companies to recruit patients for clinical trials.

“We’re thrilled to partner with Lyft to offer patients enrolled in clinical trials a new level of convenience,” said Nariman Nasser, vice president of site optimization at Continuum Clinical. “We believe that this service will make enrolling and staying in a study easier, especially for those patients with limited resources and access to transportation.”

Lack of transportation is frequently cited as a barrier to retaining patients in clinical trials. Through Continuum’s partnership with Lyft, patients enrolled in clinical trials will be able to use the Lyft app to secure transportation to and from the trial site, free of charge.

The program will help to ensure that patients enrolled in the trials won’t miss appointments, which may potentially disqualify them from the trial. Continuum plans on trialing the Lyft program this quarter for a national study on lupus.

“Through our partnership with Continuum Clinical, we’re able to provide patients with safe, affordable and reliable rides,” said Gyre Renwick, head of enterprise healthcare partnerships at Lyft. “We look forward to working with Continuum to help the community get around more efficiently.”

In 2016, Lyft partnered with a number of senior care providers and healthcare systems for non-emergency transportation services. Continuum Clinical will be a preferred provider for clinical trial transportation solutions.

For over 20 years, Continuum Clinical has worked with eight of the top ten pharmaceutical companies around the world to recruit patients for clinical trials through integrated marketing efforts. They have recruited patients in more than 600 studies in over 75 disease states. Currently, Continuum is working with over 1,900 active study sites throughout the U.S.

About Continuum Clinical

Continuum Clinical is a global healthcare research and communications company. With over thirty years of experience, Continuum Clinical brings together a unique blend of world-class experience in key disciplines, including observational research, marketing, communications, site optimization health economics, and outcomes research. We excel in providing seamless resources for pharmaceutical and biotech products — from patient recruitment and retention for clinical trials to late stage studies and health economics and outcomes research. Continuum Clinical provides a unique blend of resources and perspectives, proven expertise, and innovative solutions throughout the entire continuum of a product’s lifecycle — from pre-launch into the real world. Headquartered in the US, Continuum Clinical has employees in Europe and expanded worldwide network of resources.
WWW.CONTINUUMCLINICAL.COM

About Lyft

Lyft was founded in June 2012 by Logan Green and John Zimmer to improve people's lives with the world's best transportation. Lyft is the fastest growing rideshare company in the U.S and is available in more than 200 cities. Lyft is preferred by drivers and passengers for its safe and friendly experience, and its commitment to effecting positive change for the future of our cities. For more information on Lyft for Healthcare, visit http://get.lyft.com/healthcare/

Josh McColough
Director, Corporate Communications
Continuum Clinical
jmccolough@continuumclinical.com
847-418-2474

Survey Reveals Increased Reliance On Observational Research Among Life Sciences Companies

read more
More pharmaceutical, medical device and biotech companies are seeking evidence on how their products perform under actual practice conditions.

CHICAGO, IL (November 28, 2016) – New research has revealed that more life sciences companies are relying on observational research studies than ever before. Ten-year aggregate results from the Annual Survey on Observational Research conducted by Continuum Clinical were released in a white paper today.

Among the findings, the survey revealed that 70% of companies surveyed either have a department or specific individuals dedicated to observational research, and an additional 19% are in the process of evaluating the need for organizational specialization.

“This finding is in stark contrast to the lack of focus and experience that inspired development of the survey several years ago,” said Jeff Trotter, President of Continuum Clinical. “Life sciences companies have clearly recognized that observational studies are critical for generating real-world evidence of clinical, economic, and humanistic value, and have responded with an increased focus internally.”

Unlike pre-approval clinical trials designed for regulatory approval, observational studies respond to the need for outcomes data on how diseases are managed or how drugs and devices are utilized under actual practice conditions.

“Prior surveys revealed sponsoring companies often imposed operational and organizational constraints on observational studies that reflected greater ‘comfort’ for the processes underlying interventional clinical trials.” said Trotter. “While there is an increase in building centers of excellence around this activity, there is still room for growth around the correct business strategy for observational research and how these critical studies are designed and implemented.”

The eleventh version of the Survey on Observational Research will be released for participation in early 2017, and will feature an increased focus on the use of advanced technology in the generation and communication of real-world evidence.

Josh McColough
Director, Corporate Communications
Continuum Clinical
jmccolough@continuumclinical.com
847-418-2474

Continuum Clinical’s Sandra Chase Named to Pharmavoice Top 100 Most Inspiring People

read more
Leading healthcare firms Blue Chip Patient Recruitment and J Trotter Research & Consulting combine to form Continuum Clinical.

NORTHBROOK, IL (August 4, 2016) – Continuum Clinical is pleased to announce that Sandra Chase, vice president of patient recruitment, has been recognized by PharmaVOICE magazine as one of the "100 Most Inspiring People in the Life-Sciences Industry."

Chase was selected by industry peers and PharmaVOICE readers for her ability to view industry trends as opportunities, and for her innovative approach to developing breakthrough strategies to improve the patient experience in clinical trails.

As vice president of patient recruitment at Continuum Clinical, Chase delivers valuable solutions to recruitment challenges. Chase has made a major impact on Continuum Clinical by growing site optimization, building the clinical enrollment specialist team, and introducing the highly successful clinical outreach specialist team.

"Sandy has been instrumental in growing the organization’s site optimization services from strategy development to identifying and incorporating key metrics that help sites meet and exceed their enrollment goals,” said Neil Weisman, executive vice president of Continuum Clinical. “Under Sandy’s leadership and commitment to demonstrating value we are building a new generation of industry experts."

Under Chases’ leadership and vision the site optimization team has grown from six employees to become one of the largest teams at Continuum Clinical with almost 40 employees to date.

Now in its 11th year, the PharmaVOICE 100 honors the most inspirational and innovative individuals in the life-sciences industry. Candidates are selected based on their ability to inspire peers through their actions, as well as exhibiting strong leadership qualities, fearless and unique approaches to problems, and innovation in strategies, products and services.

The PharmaVOICE 100 honorees represent a broad cross section of the global life-sciences industry, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, advertising, digital, marketing, technology, academia, and many other sectors.

The company will be headquartered in Northbrook, Ill., with staff located off-site in strategic locations globally.

About Continuum Clinical
Continuum Clinical facilitates aligned clinical and commercial thinking through strategic, balanced and thoughtful solutions built around three distinct service offerings: Patient Recruitment and Late-Stage Research (including Health Economics and Outcomes Research). Continuum Clinical is uniquely positioned to achieve patient engagement in support of clinical trials, and to establish and communicate evidence of the value of medical products to key stakeholders, such as physicians, patients and payers. With headquarters outside of Chicago and staff strategically located globally, Continuum Clinical meets the clinical development and commercialization needs of leading pharmaceutical, biotech and medical device companies.

Author: Courtney Cymerman
Blue Chip Marketing Worldwide
CCymerman@bluechipww.com
847-418-8040

Survey shows need for greater consistency in "real world" observational research

read more
Ninth annual survey reveals that drug and device companies understand the value of real world studies, but continue to struggle with strategic, operational and organizational hurdles.

NORTHBROOK, Ill (July 27, 2015) – According to a recent survey, the pharmaceutical, biotech, and medical device industries are aware of the benefits of observational research in better understanding the real world value of their products; however, there is continued need to improve the design and implementation of the studies.

Results from the 9th Annual Survey on Observational Research conducted by Continuum Clinical were released in a white paper today.

While more traditional controlled clinical trials are the conventional pathway for regulatory approval of drugs, observational studies are increasingly viewed as essential for companies interested in understanding how their products perform under actual medical conditions.

"Controlled clinical research remains the gold-standard for regulatory approval,” said Jeff Trotter, President of Continuum Clinical, and author of the survey. “But other stakeholders including payers, physicians, and patients need to understand a product’s clinical, economic and humanistic value once it is approved and being prescribed and utilized in the 'real world.' As a result, drug and device companies must generate these data through studies that are designed and implemented under post-approval conditions."

The survey reveals ten key findings about prospective observational studies, and identifies opportunities for drug and device companies to improve the implementation of real world research. Among the key findings were:

  • 70% of respondents see their organizations becoming increasingly involved with observational studies, and 75% see their company “comfort level” improving
  • Less than half of respondents indicated that their organizations had Standard Operating Procedures (SOPs) specific to observational studies
  • 83% of respondents felt constrained in utilizing vendors [for observational research] that don’t understand observational research
  • A vastly underutilized source for enrolling patients into observational studies was “patients interested in but not qualifying for pre-approval clinical trials”

Trotter added, "What we’re seeing is that there’s strong consensus that observational research is critical, but a lot of confusion regarding how to efficiently and effectively implement the st

Over its nine iterations, the survey has enjoyed the participation of approximately 2,000 respondents worldwide who represent a cross-section of the pharmaceutical industry and job functions.

For complete survey results and to download the 9th Survey on Observational Research, visit www.continuumclinical.com/research.

Author: Josh McColough
Continuum Clinical, LLC
josh.mccolough@continuumclinical.com
847-418-2474

Creativ-Ceutical and Continuum Clinical form Strategic Alliance

read more
Industry leaders in developing evidence of medical product value collaborate to serve clients.

NORTHBROOK, Ill (April 14, 2015) – Creativ-Ceutical and Continuum Clinical have formed a strategic alliance to expand their global reach and capabilities to further meet the needs of their pharmaceutical, biotech and medical device company clients.

Leveraging the combined experience of over 130 research professionals located in Europe, the US, Asia and the Middle East, the strategic alliance enables both organizations to offer a full suite of comprehensive health economics and outcomes research (HEOR) services, real-world evidence, medical communications and market access capabilities.

Through their linked operational processes, Creativ-Ceutical and Continuum develop the full range of research-based evidence to ensure products ultimately achieve their documented benefits in improving cost-effective patient outcomes.

"We are pleased to announce our partnership with Continuum Clinical”, said Professor Mondher Toumi, CEO and founder of Creativ-Ceutical. “Continuum Clinical’s industry-leading experience in the design and implementation of patient registries, and other prospective observational, real-world studies complements our strengths in HEOR and market access services."

Jeff Trotter, President of Continuum Clinical, commented

"The team at Creativ brings state-of-the-art insights to developing and implementing HEOR and market access strategies. We are excited about working with Creativ because they share our passion for conducting research activities that will enable our clients to credibly establish and persuasively communicate the clinical, economic, and humanistic value of their innovative products."

About Creativ-Ceutical

Creativ-Ceutical (C-C) is an international consulting firm dedicated to supporting the life science industry and health authorities in strategic decision-making. C-C provides market access and pricing services that combine strong technical know-how with strategic expertise and deliver value at all stages of development and commercialization. www.thecolorofhealth.com

About Continuum Clinical

Over its nine iterations, the survey has enjoyed the participation of approximately 2,000 respondents worldwide who represent a cross-section of the pharmaceutical industry and job functions.

Based in suburban Chicago, Continuum Clinical is a healthcare research and communications company focusing on three interrelated businesses—Patient Recruitment for clinical trials; Late Stage research (observational studies and health economics); and Medical Communications—representing a unique blend of world-class experience in post-approval research, marketing, communications, health economics and outcomes research. www.continuumclinical.com

Author: Josh McColough
Continuum Clinical, LLC
josh.mccolough@continuumclinical.com
847-418-2474

Patient Recruitment and Late-Stage Research Companies Merge

read more
Leading healthcare firms Blue Chip Patient Recruitment and J Trotter Research & Consulting combine to form Continuum Clinical.

NORTHBROOK, Ill (September 10, 2014) – Suburban Chicago-based healthcare firms Blue Chip Patient Recruitment (BCPR) and J Trotter Research & Consulting (JTRC) have merged to form Continuum Clinical. The new company combines the BCPR specialty of patient recruitment for clinical trials and the JTRC expertise of late-stage (post-approval) research, and will also offer medical communications services.

"Continuum Clinical is uniquely positioned in the market to provide three distinct, yet interrelated services to pharmaceutical and medical device companies," said Jeff Trotter, the president of Continuum. "This new venture represents a convergence of services and robust capabilities that respond to the increasingly aligned needs of clinical researchers and product commercialization professionals."

Continuum will capitalize on BCPR’s twenty years of experience recruiting patients for over 600 clinical trials, as well as its communication, public relations, digital, advertising and media buying capabilities. In addition, Continuum builds on JTRC’s thirty-year legacy in health economics and outcomes research, observational studies and patient registries, and an extensive track record of publications.

"We are excited to build upon our path of transformational growth by offering our current and potential clients even more depth of services,” said Neil Weisman, executive vice president and general manager of Continuum’s patient recruitment practice (which will retain the BCPR branding through 2014). "Our expanded platform will enhance our capabilities in both site and patient engagement in all phases of clinical research."

By offering the three related services to major pharmaceutical and medical device clients, Continuum Clinical facilitates greater internal synergies and efficiencies in establishing and communicating the value of clients’ medical product innovations to physicians, patients, and payers.

"Our credentials with multiple stakeholders within our client companies is what sets us apart,” said Trotter. “And we are intimately familiar with both the challenges and the considerable opportunities that exist when commercial and clinical teams work together."

The company will be headquartered in Northbrook, Ill., with staff located off-site in strategic locations globally.

Author: Josh McColough
Continuum Clinical, LLC
josh.mccolough@continuumclinical.com
847-418-2474
Back to Top